Relates to Heterocyclic compounds of formula (IA) or (IB) where the substituents Z, W2, R4, R7, R8, W, D, L, N, Q, e, G, r, R1, R2, AR1, ar2, D1, L1, Q1, M, W1, R3, R5, R6, W3, Z1, and R9, R10, R11, R12, AR3, K, K1 and Y1 are as described in the specification. Preferred compounds of formula Ia IB - 1, - 2, among others. It also relates to a Pharmaceutical combination.These compounds inhibit the NS5A Protein of hepatitis C virus (HCV) is useful in the treatment and Prevention of infection by hepatitis C virusSE REFIERE A COMPUESTOS HETEROCICLOS DE FORMULAS (Ia) Y (Ib) DONDE LOS SUSTITUYENTES Z, W2, R4, R7, R8, W, D, L, Q, n, E, G, R1, R2, Ar, Ar1, Ar2, D1, L1, Q1, m, W1, R3, R5, R6, W3, Z1, Y, R9, R10, R11, R12, Ar3, K, K1 E Y1 SON DE ACUERDO A LO DESCRITO EN LA MEMORIA DESCRIPTIVA. SON COMPUESTOS PREFERIDOS LOS DE FORMULA Ia-1, Ib-2, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMBINACION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA PROTEINA NS5A DEL VIRUS DE LA HEPATITIS C (HCV) SIENDO UTILES EN EL TRATAMIENTO Y PREVENCION DE LA INFECCION POR EL VIRUS DE LA HEPATITIS C
